Biotech company Acrux is on its way to sharing in milestone and royalty payments which could hit $1 billion thanks to a growing market of middle-aged men who still want to be able to have sex.
Acrux received approval from the US Food and Drug Administration yesterday for its Axiron testosterone supplement therapy, which it hopes to be selling by next April.
Mr Treagus said Axiron's point of difference was its unique delivery system - an underarm spray. Acrux is also seeking to patent that method, which would extend its copyright protection until 2026.
No comments:
Post a Comment